EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY-NC 4.0

Prescription of guideline‐directed medical therapies in patients with diabetes and chronic kidney disease from the CURE‐CKD Registry, 2019‐2020

Susanne B Nicholas iD, Kenn B Daratha, Radica Z Alicic iD, Cami R Jones, Lindsey M Kornowske, Joshua J Neumiller, Samuel T Fatoba, Sheldon X Kong, Rakesh Singh, Keith C Norris, Katherine R Tuttle iD

Diabetes, Obesity and Metabolism · 2023-10 · 25 (10) · 2970-2979

DOI: 10.1111/dom.15194 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 03.07.2023. Verfasst von Susanne B Nicholas und 10 weiteren Autor:innen. Beteiligte Einrichtung: Nephrology Division, David Geffen School of Medicine, University of California, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Renal Insufficiency, Chronic, Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 76-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIDDK NIH HHS, NCATS NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Guideline‐directed medical therapy (GDMT) is designed to improve clinical outcomes. The study aim was to assess GDMT prescribing rates and prescribing‐persistence predictors in patients with diabetes and chronic kidney disease (CKD) from the Center for Kidney Disease Research, Education, and Hope Registry. Materials and Methods Data were obtained from adults ≥18 years old with diabetes and CKD between 1 January 2019 and 31 December 2020 (N = 39 158). Baseline and persistent (≥90 days) prescriptions for GDMT, including angiotensin converting enzyme (ACE) inhibitor/angiotensin receptor blocker (ARB), sodium‐glucose cotransporter‐2 (SGLT2) inhibitor and glucagon‐like peptide 1 (GLP‐1) receptor agonist were assessed.

Results

The population age (mean ± SD) was 70 ± 14 years, and 49.6% (n = 19 415) were women. Baseline estimated glomerular filtration rate (2021 CKD‐Epidemiology Collaboration creatinine equation) was 57.5 ± 23.0 ml/min/1.73 m 2 and urine albumin/creatinine 57.5 mg/g (31.7‐158.2; median, interquartile range). Baseline and ≥90‐day persistent prescribing rates, respectively, were 70.7% and 40.4% for ACE inhibitor/ARB, 6.0% and 5.0% for SGLT2 inhibitors, and 6.8% and 6.3% for GLP‐1 receptor agonist (all p < .001). Patients lacking primary commercial health insurance coverage were less likely to be prescribed an ACE inhibitor/ARB [odds ratio (OR) = 0.89; 95% confidence interval (CI) 0.84‐0.95; p < .001], SGLT2 inhibitor (OR 0.72; 95% CI 0.64‐0.81; p < .001) or GLP‐1 receptor agonist (OR 0.89; 95% CI 0.80‐0.98; p = .02). GDMT prescribing rates were lower at Providence than UCLA Health.

Conclusions

Prescribing for GDMT was suboptimal and waned quickly in patients with diabetes and CKD. Type of primary health insurance coverage and health system were associated with GDMT prescribing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes MellitusRenal Insufficiency, ChronicSodium-Glucose Transporter 2 InhibitorsDiabetes Mellitus, Type 2AdultHumansFemaleMiddle AgedAgedAged, 80 and overAdolescentMaleCreatinineAngiotensin Receptor AntagonistsGlucagon-Like Peptide-1 ReceptorAngiotensin-Converting Enzyme InhibitorsPrescriptionsRegistries

Stichwörter der Autor:innen

diabetic nephropathyelecronic health records datakidney and cardiovascular protective drugsreal-world evidencetype 2 diabetes

Substanzen

CreatinineAngiotensin Receptor AntagonistsGlucagon-Like Peptide-1 ReceptorAngiotensin-Converting Enzyme InhibitorsSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Nephrology Division, David Geffen School of Medicine, University of California, Los Angeles, California, USA.
  • Providence Medical Research Center, Providence Inland Northwest, Spokane, Washington, USA.
  • Department of Medicine, University of Washington, Seattle, Spokane, Washington, USA.
  • Department of Pharmacotherapy, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, Washington, USA.
  • Bayer US, LLC, Medical Affairs, Whippany, Whippany, USA.
  • Kidney Research Institute, Institute of Translational Health Sciences, University of Washington, Seattle, Washington, USA.

ORCID-Profile: Susanne B Nicholas, Radica Z Alicic, Katherine R Tuttle

Förderung

  • NIDDK NIH HHS
  • NCATS NIH HHS
  • NHLBI NIH HHS
  • NIA NIH HHS
  • NIMHD NIH HHS
  • Bayer

Zitieren

APA

Nicholas, S. B., Daratha, K. B., Alicic, R. Z., Jones, C. R., Kornowske, L. M., Neumiller, J. J., Fatoba, S. T., Kong, S. X., Singh, R., Norris, K. C., & Tuttle, K. R. (2023). Prescription of guideline‐directed medical therapies in patients with diabetes and chronic kidney disease from the CURE‐CKD Registry, 2019‐2020. Diabetes, Obesity and Metabolism, 25(10), 2970-2979. https://doi.org/10.1111/dom.15194

Vancouver

Nicholas SB, Daratha KB, Alicic RZ, Jones CR, Kornowske LM, Neumiller JJ, et al. Prescription of guideline‐directed medical therapies in patients with diabetes and chronic kidney disease from the CURE‐CKD Registry, 2019‐2020. Diabetes, Obesity and Metabolism. 2023;25(10):2970-2979. doi:10.1111/dom.15194

BibTeX
@article{Nicholas2023,
  author = {Nicholas, Susanne B and Daratha, Kenn B and Alicic, Radica Z and Jones, Cami R and Kornowske, Lindsey M and Neumiller, Joshua J and Fatoba, Samuel T and Kong, Sheldon X and Singh, Rakesh and Norris, Keith C and Tuttle, Katherine R},
  title = {Prescription of guideline‐directed medical therapies in patients with diabetes and chronic kidney disease from the CURE‐CKD Registry, 2019‐2020},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2023},
  volume = {25},
  number = {10},
  pages = {2970--2979},
  doi = {10.1111/dom.15194}
}
Kostenlos starten →